| Literature DB >> 30903806 |
Sheila Isanaka1,2, Matt D T Hitchings3, Fatou Berthé4, André Briend5,6, Rebecca F Grais2.
Abstract
Efforts to reduce the impact of stunting have been largely independent of interventions to reduce the impact of wasting, despite the observation that the conditions can coexist in the same child and increase risk of death. To optimize the management of malnourished children-who can be wasted, stunted, or both-the relationship between stunting and wasting should be elaborated. We aimed to describe the relationship between concurrent weight and height gain during and after rehabilitation from severe wasting. We conducted a secondary analysis of a randomized trial for the outpatient treatment of severe wasting, including 1,542 children who recovered and were followed for 12 weeks. We described the overlap of stunting and severe wasting and the change in stunting over time. We showed the relationship between concurrent weight and height gain using adjusted generalized estimating equations and calculated the mean rate of change in weight-for-height z score (WHZ) and height-for-age z score (HAZ) during and after rehabilitation. At baseline, 79% (n = 1,223/1,542) and 49% (n = 757/1,542) of children were stunted and severely stunted, respectively. Prevalence increased over time among children <24 months. During rehabilitation when weight was not yet fully recovered, we found rapid WHZ gain but limited HAZ gain. Following successful rehabilitation, WHZ gain slowed. The rate of HAZ gain was negative after rehabilitation but increased relative to the period during treatment. The potential relationship between weight and height gain calls for increased coverage of wasting treatment to not only prevent child mortality but also reduce linear growth faltering.Entities:
Keywords: Niger; child malnutrition; linear growth; stunting; wasting; weight gain
Mesh:
Year: 2019 PMID: 30903806 PMCID: PMC6849732 DOI: 10.1111/mcn.12817
Source DB: PubMed Journal: Matern Child Nutr ISSN: 1740-8695 Impact factor: 3.092
Baseline characteristics of study population
| Characteristic | Total ( | Severely wasted only ( | Severely wasted and stunted ( |
|
|---|---|---|---|---|
| Sociodemographic characteristics | ||||
| Child age (month) | 17.4 ± 8.6 | 12.7 ± 6.9 | 18.6 ± 8.5 | <0.0001 |
| Mother age (year) | 27.2 ± 6.7 | 26.8 ± 6.2 | 27.3 ± 6.8 | 0.34 |
| Male sex | 746 (48.4) | 126 (39.5) | 620 (50.7) | 0.0004 |
| Maternal education (primary school complete or higher) | 236 (15.3) | 51 (16.0) | 185 (15.1) | 0.70 |
| No. of household members | 7.4 ± 3.9 | 7.3 ± 3.8 | 7.4 ± 3.9 | 0.92 |
| Anthropometric data | ||||
| WHZ | −3.0 ± 0.6 | −3.0 ± 0.6 | −3.0 ± 0.6 | 0.18 |
| WHZ < −3 | 878 (56.9) | 195 (61.1) | 683 (55.9) | 0.09 |
| MUAC (mm) | 112.8 ± 4.1 | 113.7 ± 3.5 | 112.6 ± 4.2 | <0.0001 |
| MUAC <115 mm | 1,193 (77.4) | 228 (71.5) | 965 (78.9) | 0.005 |
| HAZ | −3.0 ± 1.2 | −1.4 ± 0.5 | −3.4 ± 1.0 | <0.0001 |
| Clinical characteristics and medical history | ||||
| Haemoglobin <11.0 g/dl | 1,150 (74.6) | 215 (67.4) | 935 (76.5) | 0.001 |
| Rapid diagnostic test positive for malaria | 904 (58.6) | 178 (55.8) | 726 (59.4) | 0.25 |
| Axillary temperature >38.5°C | 72 (4.7) | 17 (5.3) | 55 (4.5) | 0.53 |
| Signs of infection in previous 24 hr | ||||
| Diarrhoea | 495 (32.1) | 108 (33.9) | 387 (31.6) | 0.45 |
| Vomiting | 91 (5.9) | 32 (10.0) | 59 (4.8) | 0.0004 |
| Cough | 273 (17.7) | 65 (20.4) | 208 (17.0) | 0.16 |
| Seen at health facility in previous 30 days | 352 (22.8) | 80 (25.1) | 272 (22.2) | 0.28 |
| Child currently breastfeeding | 918 (60.0) | 258 (80.1) | 660 (54.0) | <0.0001 |
Values are n (%) or mean ± SD
p value from a t test for continuous variables and from a chi‐square test of independence for categorical variables.
Prevalence of stunting and severe stunting over 12 weeks from admission among children 6–23 months and 24–59 months of age
| Prevalence at baseline | Prevalence at end of follow up | |
|---|---|---|
| 6–23 months of age | ||
| Stunting | 76.1% | 86.8% |
| Severe stunting | 43.6% | 55.5% |
| 24–59 months of age | ||
| Stunting | 94.8% | 94.4% |
| Severe stunting | 75.3% | 78.3% |
P for difference between prevalence at baseline versus end of follow‐up <0.05.
Figure 1Mean change in weight‐for‐height z score (solid) and height‐for‐age z score (dashed) during and following treatment estimated from generalized estimated equations, with 95% confidence intervals shown as dotted lines, for an 18‐month‐old boy in the placebo group. A * denotes that post‐treatment change is significantly different from pretreatment change (p < .05)